GLP #2 has also demonstrated success over the long term
However, it distinguishes itself by acting on two additional hormones: glucose-dependent insulinotropic polypeptide (GIP), which aids in blood sugar management, and glucagon, which can help suppress appetite and increase energy expenditure
In the meta-analysis of 3 studies 20,28,32 which compared a GLP-1-based therapy against a comparator, GLP-1-based therapies were found to increase % FMD non-significantly (mean difference [95% CI] in the changes from baseline: 1.65 [0.89, 4.18] %
For us, the WeightWatchers brand lives in how we show up every daythrough our experience, our coaches, our community, and our medical support, said Julie Rice, chief experience officer at WeightWatchers
No clinical trial has tested the retatrutide+cagrilintide combination as of May 2026
J Obes Metab Syndr 2023;32:2545.ArticlePubMedPMC 87